- The latest Entresto data showed better results than using the proven therapy, enalapril, to start a Novartis drug in a hospital for heart attack patients.
- In the PIONEER-HF study, Entresto patients showed significant biomarkers with severity and prognosis reduced by about 30% compared to enalapril. Within one week after starting Entrepo, NT-proBNP (hormone release due to pressure changes inside the heart) was significantly reduced.
- Patients taking Novartis medication 8 weeks after treatment versus nalapril were reduced by 46% of the following risk factors: He was re-admitted to a heart attack; LVAD insertion required; It is listed for heart transplantation. And death.
Novartis' clinical programs for Entarto (sacubitril and valsartan), including PIONEER and TRANSITION, have accumulated a vast amount of data over the last few years. Swiss pharmaceutical company PIONEER-HF believes that Entresto has the necessary evidence to support the low mortality rate and the basic rehabilitation of heart attack patients with high hospital re-entry rates.
Shreeram Aradhye, Chief Medical Officer at Novartis Pharmaceuticals, said in a November 11 statement, "Through the Entresto Science Program, we are re-imagining the use of Entresto as a standard of care and basic cure for HFrEF patients.
The results were presented at a meeting of the American Heart Association over the weekend and were published in the New England Journal of Medicine.
Novartis received Entresto's initial approval in the US in July 2015, and initial approval in the EU a few months later. You can get a Class 1 recommendation in both regions in 2016.
Drug sales are growing rapidly, and in the third quarter worldwide, it increased by more than 100% to $ 271 million.
There is more data in the future. The expected PARAGON studies are under way in the mid-1970's and patients with degenerative fractions are preserved. And the PARADISE study that tests Entresto in patients with pre-cardiac arrest, heart failure, is enrolled according to plan.
"Overall, the Entresto picture is looking strong, we continue to see the hard momentum of the world with this drug," said Novasis CEO Vas Narasimhan, the company's third quarter call.